Drugs / Zinpentraxin Alfa
Zinpentraxin Alfa
also known as
PRM 151 · recombinant human pentraxin-2 · Pentraxin 2 (human) · Pentraxin-2 · Ptx-2 · Recombinant human serum amyloid p · RG-30326 · RG-6354 · +5 more
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01254409 | Mar 2011 → Jul 2012 | idiopathic pulmonary fibrosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02550873 | Sep 2015 → May 2017 | idiopathic pulmonary fibrosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01981850 | Oct 2013 → Jul 2020 | acquired polycythemia vera, myelofibrosis, primary myelofibrosis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01064817 | Jun 2010 → Apr 2012 | glaucoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04594707 | Aug 2021 → Feb 2023 | idiopathic pulmonary fibrosis | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT04552899 | Mar 2021 → Feb 2023 | idiopathic pulmonary fibrosis | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zinpentraxin alfa | “Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant form of PTX-2 that has shown preclinical antifibrotic activity and no dose-limiting toxicities in phase I trials.” PMID 37165840 ↗ Oct 2023 |
| Known as | Pentraxin 2 (human) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297814 ↗ |
| Known as | Pentraxin-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297814 ↗ |
| Known as | PRM 151 | “PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks” NCT02550873 ↗ |
| Known as | Ptx-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297814 ↗ |
| Known as | recombinant human pentraxin-2 | “recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo” NCT04552899 ↗1“PRM-151 (recombinant human pentraxin-2, also known as serum amyloid P)” PMID 26869678 ↗ Feb 2016 |
| Known as | Recombinant human serum amyloid p | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297814 ↗ |
| Known as | RG-30326 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297814 ↗ |
| Known as | RG-6354 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297814 ↗ |
| Known as | rhPTX-2 | “recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo” NCT04552899 ↗ |
| Known as | RO7490677 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01981850 ↗ |
| Known as | serum amyloid P | “PRM-151 (recombinant human pentraxin-2, also known as serum amyloid P)” PMID 26869678 ↗ Feb 2016 |
| Known as | Zinpentraxin alfa component of amyloid p , serum, recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297814 ↗ |
| Known as | Zinpentraxin alfa component of serum amyloid p-, recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297814 ↗ |
| Action | Inhibit | “hSAP prevented the recruitment of fibrocytes into the injured liver and their differentiation into myofibroblasts.” PMID 39761005 ↗ Oct 2024 |
| Modality | Protein / enzyme biologic | “PRM-151 (recombinant human serum amyloid P, recombinant human pentraxin 2)” NCT01064817 ↗ |
| Route | Other | “PRM-151 administered as a subconjunctival injection” NCT01064817 ↗ |